NCT05154123

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

A Phase 1, Open-Label Study to Evaluate the Effect of AT-527 on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Drug-drug interaction study of rosuvastatin and AT-527 (R07496998)

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	Drug: AT-527 + rosuvastatin	* Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.
DRUG	AT-527 + rosuvastatin	* Day 1: A single dose of rosuvastatin will be administered. * Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)

Timeline

• Start date: 2021-11-16
• Primary completion: 2021-12-23
• Completion: 2021-12-23
• First posted: 2021-12-10
• Last updated: 2022-02-25

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study